Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
FDA Grants Fast Track Designation for Novel Sepsis Treatment Isupartob
FDA Grants Fast Track Designation for Novel Sepsis Treatment Isupartob
Read also
Alzheimer's Clinical Trials: First Patient Dosed with Leronlimab
CytoDyn and Weill Cornell Medicine initiate a Phase 2a clinical study, dosing the first Alzheimer's disease patient with humanized monoclonal antibody leronlimab.
FDA Expands Approval of Sanofi's Tzield for Type 1 Diabetes in Kids
Sanofi's Tzield receives an expanded FDA drug approval for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes.
Prader-Willi Syndrome Treatment: Setmelanotide Phase 2 Results
Rhythm Pharmaceuticals reports a significant 7-point hyperphagia reduction in its Phase 2 trial of setmelanotide for Prader-Willi syndrome.
Symeres Expands Spray Drying Capabilities for Complex Drug Formulation
Symeres enhances its CMC site in New Jersey with expanded spray drying capabilities, optimizing drug formulation development for poorly soluble candidates.
